Advertisement

Reactions Weekly

, Volume 1673, Issue 1, pp 6–6 | Cite as

Kymriah approved despite $475 000 price and toxicities

News item
  • 49 Downloads

Reference

  1. Bach PB, et al. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. Journal of the American Medical Association : 20 Sep 2017. Available from: URL:  http://dx.doi.org/10.1001/jama.2017.15218

Copyright information

© Springer International Publishing AG 2017

Personalised recommendations